Dr. Reddy's stock: Brazil approves generic semaglutide

Published on 11/06/2026 at 01:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr. Reddy's stock gains a new Brazil opportunity after ANVISA approved its generic semaglutide injection. Aché will support the launch.

Brazil expands diabetes portfolio

ANVISA authorized a once-weekly generic semaglutide injection in two pre-filled pen strengths.
Dr. Reddy's plans to launch the product in Brazil with Aché, targeting a major diabetes market.
The company operates across generics, API and services, innovative medicines, and consumer health.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

Brazil's health regulator ANVISA has granted Dr. Reddy's Laboratories marketing authorization for a generic semaglutide injection, according to RTT News. The report was published on Thursday, November 5, 2026.

Approval targets Brazil demand

The authorization covers a once-weekly, pre-filled multi-dose pen for adults with inadequately controlled type 2 diabetes. The product is available in 2 mg/1.5 mL and 4 mg/3 mL strengths, and may be used alone when metformin is unsuitable or alongside other diabetes medicines.

Dr. Reddy's plans to launch the treatment in Brazil through a partnership with Aché. RTT News cited company estimates of about 16.6 million adults living with diabetes in Brazil and a semaglutide diabetes-treatment market worth about 244.6 million US dollars.

Portfolio broadens through partnerships

The Brazil authorization adds another commercial step to Dr. Reddy's semaglutide strategy and expands its presence in a major Latin American market. It also illustrates the company's use of regulatory approvals and local partnerships to extend access to medicines beyond its home markets.

Business spans four segments

Dr. Reddy's operates across generics, API and services, innovative medicines, and consumer health. Its portfolio includes branded and unbranded generics, biosimilars, research and manufacturing support, and licensed products. The company says it expands its global reach through in-licensing and partnerships with innovative healthcare companies.